1. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1(1):a006841.

2. Centers for Disease Control and Prevention. Trends in HIV-2 diagnoses and use of the HIV-1/HIV-2 differentiation test—United States, 2010–2017. MMWR. 2020;69(3);63-66.

3. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv. Last accessed March 1, 2025.

4. Pepperrell T, Hill A, Cross S. Lower prevalence countries outside of South-Eastern Africa now have the fastest growing HIV epidemic. OFID. 2024;11(7):ofae318.

5. World Health Organization. HIV/AIDS: Key Facts. Available at https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Last accessed March 1, 2025.

6. U.S. Department of State. PEPFAR Latest Global Results and Projections Factsheet (Dec. 2024). Available at https://www.state.gov/pepfar-latest-global-results-factsheet-dec-2024. Last accessed March 1, 2025.

7. Joint United Nations Programme on HIV/AIDS. 2024 Global Aids Report, The Urgency of Now: AIDS at a Crossroads. Available at https://www.unaids.org/sites/default/files/media_asset/2024-unaids-global-aids-update_en.pdf. Last accessed March 1, 2025.

8. Centers for Disease Control and Prevention. Fast Facts: HIV in the United States. Available at https://www.cdc.gov/hiv/data-research/facts-stats/index.html. Last accessed March 1, 2025.

9. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2018–2022. HIV Surveillance Supp Report. 2024;29(1):1-31.

10. Centers for Disease Control and Prevention. National HIV Behavioral Surveillance: Current Data Releases. Available at https://www.cdc.gov/hiv-data/nhbs/#cdc_survey_profile_reports_data_sets_and_publications-current-data-releases. Last accessed March 1, 2025.

11. Melhuish A, Lewthwaite P. Natural History of HIV and AIDS. Medicine. 2022;50(5):298-303.

12. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33-39.

13. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. Guide to Clinical Preventive Services, 2014. Available at https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-providers/guidelines-recommendations/guide/cpsguide.pdf. Last accessed March 1, 2025.

14. U.S. Preventive Services Task Force. Human Immunodeficiency Virus (HIV) Infection: Screening, June 2019. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/human-immunodeficiency-virus-hiv-infection-screening. Last accessed March 1, 2025.

15. Branson BM, Owen SM, Wesolowski LG, et al. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at https://stacks.cdc.gov/view/cdc/23447. Last accessed March 1, 2025.

16. U.S. Preventive Services Task Force. Final Recommendation Statement, Prevention of Acquisition of HIV: Preexposure Prophylaxis. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis. Last accessed March 1, 2025.

17. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, National Minority AIDS Council, Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014: Summary for Clinical Providers. Rockville, MD: U.S. Department of Health and Human Services; 2014.

18. Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines, 2021. Available at https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf. Last accessed March 1, 2025.

19. International Association of Providers of AIDS Care. Viral Load. Available at https://www.iapac.org/fact-sheet/viral-load. Last accessed March 1, 2025.

20. Richard Kaufman; ART and science of keeping HIV out of the blood supply. Blood. 2020;136(11):1223-1224.

21. Leveton LB, Sox HC Jr, Stoto MA (eds). HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Washington, DC: National Academies Press; 1995.

22. Centers for Disease Control and Prevention. HIV Surveillance Special Report: HIV Infection Risk, Prevention, and Testing Behaviors Among Persons Who Inject Drugs National HIV Behavioral Surveillance, 20 U.S. Cities, 2022. Available at https://stacks.cdc.gov/view/cdc/150464. Last accessed February 10, 2024.

23. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv. Last accessed March 1, 2025.

24. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections. Last accessed March 1, 2025.

25. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections. Last accessed March 1, 2025.

26. National Institutes of Health. HIV and Specific Populations. HIV and Older People. Available at https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-older-people. Last accessed March 1, 2025.

27. Occupational Safety and Health Administration. Standard 1910.1030 Bloodborne Pathogens. Available at https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030. Last accessed March 1, 2025.

28. Trickey A, Zhang L, Sabin CA, Sterne JA. Life expectancy of people with HIV on long-term antiretroviral therapy in Europe and North America: a cohort study. Lancet Healthy Longev. 2022;3(S2).

29. Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med. 2013 Nov 27;11:251.

30. Abadie RB, Brown EM, Campbell JR, et al. Incidence and risks of HIV infection, medication options, and adverse effects in accidental needle stick injuries: a narrative review. Cureus. 2024;16(1):e51521.

31. Stadelman-Behar AM, Gehre MN, Atallah L, et al. Investigation of presumptive HIV transmission associated with receipt of platelet-rich plasma microneedling facials at a spa among former spa clients—New Mexico, 2018–2023. MMWR. 2024;73(16):372-376.

32. World Health Organization. Global HIV Programme: Mother-to-Child Transmission of HIV. Available at https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/mother-to-child-transmission-of-hiv. Last accessed March 1, 2025.

33. Lampe MA, Nesheim SR, Oladapo KY, et al. Achieving elimination of perinatal HIV in the United States. Pediatrics. 2023;151(5): e2022059604.

34. Abuogi L, Noble L, Smith C. Infant feeding for persons living with and at risk for HIV in the United States: clinical report. Pediatrics. 2024;153(6):e2024066843.

35. Panel on Antiretroviral Guidelines for Adults and Adolescents. Considerations for Use of Antiretroviral Drugs in Special Populations. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations-adolescents-and. Last accessed March 1, 2025.

36. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl. 2008;14(11):1603-1608.

37. Centers for Disease Control and Prevention. HIV transmitted from a living organ donor—New York City, 2009. MMWR. 2011;60(10):297-301.

38. Centers for Disease Control and Prevention. Notes from the field: occupationally acquired HIV infection among health care workers–United States, 1985–2013. Available at https://www.cdc.gov/hiv/pdf/workplace/cdc-hiv-healthcareworkers.pdf. Last accessed March 1, 2025.

39. Kuhar DT, Henderson DK, Struble KA, et al. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis. Available at https://stacks.cdc.gov/view/cdc/20711. Last accessed March 1, 2025.

40. Centers for Disease Control and Prevention. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. Available at https://stacks.cdc.gov/view/cdc/38856. Last accessed March 1, 2025.

41. Abuogi L, Noble L, Smith C, Committee on Pediatric and Adolescent HIV, Section on Breastfeeding. Infant feeding for persons living with and at risk for HIV in the United States: clinical report. Pediatrics. 2024;153(6):e2024066843.

42. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. United States Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. Last accessed March 1, 2025.

43. U.S. Food and Drug Administration. FDA-Approved HIV Medicines. Available at https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines. Last accessed March 1, 2025.

44. Tram KH, Ratevosian J, Beyrer C. By executive order: the likely deadly consequences associated with a 90-day pause in PEPFAR funding. J Int AIDS Soc. 2025;28(3):e26431.

45. UNAIDS. Impact of U.S. Cuts on Global AIDS Response. Available at https://www.unaids.org/en/resources/presscentre/featurestories/2025/march/20250304-update-us-funding-freeze-fs. Last accessed March 1, 2025.

46. U.S. Food and Drug Administration. December 16, 2024 Approval Order–OraQuick HIV Self-Test. Available at https://www.fda.gov/media/184589/download?attachment=&utm_medium=email&utm_source=govdelivery. Last accessed March 1, 2025.

47. Larson KB, Wang K, Delille C, Otofokun I, Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet. 2014;53(10):865-872.

48. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.

49. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-822.

50. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections. Last accessed March 1, 2025.

51. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2023. Available at https://www.cdc.gov/tb-surveillance-report-2023/summary/national.html. Last accessed March 1, 2025.

52. World Health Organization. Tuberculosis. Available at https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Last accessed March 1, 2025.

53. Kaiser Family Foundation. the Impact of HIV on Women in the United States. Available at https://www.kff.org/hivaids/fact-sheet/women-and-hivaids-in-the-united-states. Last accessed March 1, 2025.

54. Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32(6):795-808.

55. American College of Obstetricians and Gynecologists. Practice Bulletin 167: gynecologic care for women and adolescents with human immunodeficiency virus. Obstet Gynecol. 2016;128(4):e89-e110.

56. The Antiretroviral Pregnancy Registry. Available at https://www.apregistry.com. Last accessed March 1, 2025.

57. U.S. Food and Drug Administration. FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv. Last accessed March 1, 2025.

58. U.S. Food and Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention. Last accessed March 1, 2025.

59. Gilead. News Release: U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review. Available at https://www.gilead.com/news/news-details/2025/us-fda-accepts-gileads-new-drug-applications-for-twice-yearly-lenacapavir-for-hiv-prevention-under-priority-review. Last accessed March 1, 2025.

60. U.S. Food and Drug Administration. Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use. Available at https://www.fda.gov/media/83586/download. Last accessed March 1, 2025.

61. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.

62. Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2021 Update: A Clinical Practice Guideline. Available at https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Last accessed March 1, 2025.

63. International AIDS Vaccine Initiative. IAVI Annual Report. Available at https://www.iavi.org/wp-content/uploads/2024/02/IAVI-2023-Annual-Report-1.pdf. Last accessed March 1, 2025.

64. Population Council. Products in Development. Available at https://popcouncil.org/cbr-products-in-development. Last accessed March 1, 2025.

65. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174.

66. Centers for Disease Control and Prevention. Youth Risk Behavior Survey Explorer. Available at https://yrbs-explorer.services.cdc.gov. Last accessed March 1, 2025.

67. Phillips G, McCuskey DJ, Felt D, et al. Association of HIV education with HIV testing and sexual risk behaviors among U.S. youth, 2009-2017: disparities between sexual minority and sexual majority youth. Prev Sci. 2020;21(7):898-907.

68. Roger AJ, Cambiano V, Brunn T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive therapy. JAMA. 2016;316(2):171-181.

69. U.S. Food and Drug Administration. FDA Approves Second Drug to Prevent HIV Infection as Part of Ongoing Efforts to End the HIV Epidemic. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic. Last accessed March 1, 2025.